Fluorothymidine F-18(Fluorothymidine F-18) - 在研适应症：急性淋巴细胞白血病，脑癌_专利_临床

概要

基本信息

药物类型

小分子化药、诊断用放射药物

别名

靶点-

作用机制

PET imaging(正电子发射断层成像术增强剂)

治疗领域

肿瘤免疫系统疾病神经系统疾病+ [1]

在研适应症

急性淋巴细胞白血病脑癌

非在研适应症

急性髓性白血病肛门肿瘤脑转移瘤+ [14]

原研机构

National Cancer Institute

在研机构

Advanced Innovative Partners Inc初创企业

非在研机构

National Institutes of Health

Weill Medical College of Cornell University

University of Oklahoma

+ [6]

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构

分子式C10H13FN2O4

InChIKeyUXCAQJAQSWSNPQ-ZIVQXEJRSA-N

CAS号287114-80-1

关联

47

项与 Fluorothymidine F-18 相关的临床试验

NCT03633955 / Recruiting临床1期IIT

Multi-institutional Prospective Pilot Study of Radiology Evaluation of Acute Leukemia Infiltration analyZed by Experimental Imaging

This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.

开始日期2023-01-19

申办/合作机构

University of Oklahoma

[+1]

NCT04309552 / Recruiting临床1期IIT

A Phase-I Trial for Simultaneous Imaging of Tumor Hypoxia and Proliferation in Patients With Treatment- Naïve High-Grade Glioma

This is a pilot study to assess a new methodology developed for High Grade Glioma (HGG). FMISO PET (Fluoromisonidazole-PET) allows researchers to study whether tumor cells lack oxygen (hypoxia). FLT PET (Fluorodeoxythymidine-PET) allows researchers to study the increase in the number of cells as a result of cell growth and cell division (proliferation). Tumors that have low oxygen levels and/or are dividing fast shall resist to standard cancer treatment. The study will compare FMISO PET and FLT PET imaging techniques with molecular biomarkers of hypoxia, angiogenesis, and cellular proliferation in tissue. proliferation).This information could help researchers develop new treatment techniques to better treat cancer.

开始日期2021-02-01

申办/合作机构

Weill Medical College of Cornell University

NCT04067115 / Active, not recruiting临床1/2期IIT

SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour Infusion in Ewing Sarcoma Patients in Combination With Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging

This study evaluates the trabectedin and irinotecan in the treatment of Ewings sarcoma, with a EWS-FLI1 mutation. Patients will also receive an infusion of 18F-FLT in combination with a Positron Emission Tomography (PET) scan to help evaluate the effect of treatment.
Phase I was completed on 11/16/2022. Phase II is actively recruiting.

开始日期2021-01-05

申办/合作机构

Sarcoma Alliance for Research through Collaboration

[+3]

100 项与 Fluorothymidine F-18 相关的临床结果

登录后查看更多信息

100 项与 Fluorothymidine F-18 相关的转化医学

登录后查看更多信息

100 项与 Fluorothymidine F-18 相关的专利（医药）

登录后查看更多信息

31

项与 Fluorothymidine F-18 相关的文献（医药）

2023-11-01·International journal of hematology

Hematopoiesis in the spleen after engraftment in unrelated cord blood transplantation evaluated by ¹⁸F-FLT PET imaging.

Article

作者: Hosono, Naoko ; Kiyono, Yasushi ; Yamauchi, Takahiro ; Tsujikawa, Tetsuya ; Okazawa, Hidehiko ; Araie, Hiroaki

Cord blood is an important donor source for allogeneic hematopoietic stem cell transplantation (allo-HSCT), with its unique composition and quality of hematopoietic cells. The proliferation site and potency of infused hematopoietic stem cells in humans may vary between stem cell sources. We investigated this possibility in a prospective, exploratory study to assess hematopoietic dynamics using the radiopharmaceutical 3'-deoxy-3'-¹⁸F-fluorothymidine (¹⁸F-FLT), a thymidine analog used in positron emission tomography imaging, before allo-HSCT and on days 50 and 180 after allo-HSCT. We evaluated 11 patients with hematological malignancies who underwent allo-HSCT [five with peripheral blood stem cell transplantation (PBSCT) and six with unrelated cord blood transplantation (UCBT)]. Before allo-HSCT, ¹⁸F-FLT uptake did not differ between the two groups. At day 50, ¹⁸F-FLT uptake in the spleen was significantly greater in the UCBT group than in the PBSCT group (p = 0.0043), with no difference in whole-body bone marrow. At day 180, the differences in spleen uptake had diminished, and there were no differences between groups in whole-body bone marrow or the spleen, except for the sternum. The persistence of splenic hematopoiesis after engraftment in the UCBT group may reflect the complex systemic homing and proliferation mechanisms of cord blood hematopoietic cells.

2023-11-01·Japanese journal of radiology

Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET.

Article

作者: Oshima, Sonoko ; Sano, Kohei ; Nakamoto, Yuji ; Arakawa, Yoshiki ; Fushimi, Yasutaka ; Okuchi, Sachi ; Sakata, Akihiko ; Mineharu, Yohei ; Wang, Yang ; Hinoda, Takuya ; Nakajima, Satoshi ; Tanji, Masahiro ; Shimizu, Yoichi ; Yoshida, Kazumichi ; Ishimori, Takayoshi ; Otani, Sayo

PURPOSEThis study aimed to investigate the uptake characteristics of ¹⁸F-fluoromisonidazole (FMISO), in mutant-type isocitrate dehydrogenase (IDH-mutant, grade 3 and 4) and wild-type IDH (IDH-wildtype, grade 4) 2021 WHO classification adult-type diffuse gliomas.MATERIALS AND METHODSPatients with grade 3 and 4 adult-type diffuse gliomas (n = 35) were included in this prospective study. After registering ¹⁸F-FMISO PET and MR images, standardized uptake value (SUV) and apparent diffusion coefficient (ADC) were evaluated in hyperintense areas on fluid-attenuated inversion recovery (FLAIR) imaging (HIA), and in contrast-enhanced tumors (CET) by manually placing 3D volumes of interest. Relative SUV_max (rSUV_max) and SUV_mean (rSUV_mean), 10th percentile of ADC (ADC_10pct), mean ADC (ADC_mean) were measured in HIA and CET, respectively.RESULTSrSUV_mean in HIA and rSUV_mean in CET were significantly higher in IDH-wildtype than in IDH-mutant (P = 0.0496 and 0.03, respectively). The combination of FMISO rSUV_mean in HIA and ADC_10pct in CET, that of rSUV_max and ADC_10pct in CET, that of rSUV_mean in HIA and ADC_mean in CET, were able to differentiate IDH-mutant from IDH-wildtype (AUC 0.80). When confined to astrocytic tumors except for oligodendroglioma, rSUV_max, rSUV_mean in HIA and rSUV_mean in CET were higher for IDH-wildtype than for IDH-mutant, but not significantly (P = 0.23, 0.13 and 0.14, respectively). The combination of FMISO rSUV_mean in HIA and ADC_10pct in CET was able to differentiate IDH-mutant (AUC 0.81).CONCLUSIONPET using ¹⁸F-FMISO and ADC might provide a valuable tool for differentiating between IDH mutation status of 2021 WHO classification grade 3 and 4 adult-type diffuse gliomas.

2023-02-01·Journal of Magnetic Resonance Imaging

Breast PET/MRI Hybrid Imaging and Targeted Tracers

Review

作者: Romeo, Valeria ; Pinker, Katja ; Helbich, Thomas H.

The recent introduction of hybrid positron emission tomography/magnetic resonance imaging (PET/MRI) as a promising imaging modality for breast cancer assessment has prompted fervent research activity on its clinical applications. The current knowledge regarding the possible clinical applications of hybrid PET/MRI is constantly evolving, thanks to the development and clinical availability of hybrid scanners, the development of new PET tracers and the rise of artificial intelligence (AI) techniques. In this state‐of‐the‐art review on the use of hybrid breast PET/MRI, the most promising advanced MRI techniques (diffusion‐weighted imaging, dynamic contrast‐enhanced MRI, magnetic resonance spectroscopy, and chemical exchange saturation transfer) are discussed. Current and experimental PET tracers (18F‐FDG, 18F‐NaF, choline, 18F‐FES, 18F‐FES, 89Zr‐trastuzumab, choline derivatives, 18F‐FLT, and 68Ga‐FAPI‐46) are described in order to provide an overview on their molecular mechanisms of action and corresponding clinical applications. New perspectives represented by the use of radiomics and AI techniques are discussed. Furthermore, the current strengths and limitations of hybrid PET/MRI in the real world are highlighted.Evidence Level2Technical EfficacyStage 2

100 项与 Fluorothymidine F-18 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Fluorothymidine F-18	-	DB14930

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑癌	临床2期	美国	-	2010-10-01
淋巴瘤	临床1期	美国	National Cancer Institute	2008-09-29
子宫内膜癌	药物发现	美国	National Institutes of Health	2012-10-01
盆腔肿瘤	药物发现	美国	National Institutes of Health	2012-10-01
脑转移瘤	药物发现	美国	Angiochem, Inc.	2011-10-01
乳腺癌	药物发现	-	Merck Sharp & Dohme Corp.	2010-04-08
喉肿瘤	药物发现	美国	National Institutes of Health	2008-03-01
口腔肿瘤	药物发现	美国	National Institutes of Health	2008-03-01
口咽肿瘤	药物发现	美国	National Institutes of Health	2008-03-01
头颈部鳞状细胞癌	药物发现	美国	National Institutes of Health	2008-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01244737 (CTgov)	临床2期	脑癌	50	[18F] FLT (New Diagnosis of Brain Tumor)	繭鹽壓構蓋選鬱憲窪願(壓簾構獵醖築襯蓋糧構) = 鏇築繭顧鹹廠窪餘廠遞製廠範鏇鹹觸窪遞衊醖 (糧襯淵廠鹽齋糧製顧簾, 構淵壓夢鹽艱淵夢選衊 ~ 鹹遞壓衊製蓋網廠繭鑰) 更多	-	2024-07-11
NCT01244737 (CTgov)	临床2期	脑癌	50	[18F] FLT (Possible Recurrent Brain Tumor)	繭鹽壓構蓋選鬱憲窪願(壓簾構獵醖築襯蓋糧構) = 壓襯襯廠鑰鹹鹽製衊鑰製廠範鏇鹹觸窪遞衊醖 (糧襯淵廠鹽齋糧製顧簾, 繭醖餘範壓廠鬱願積廠 ~ 齋網積築廠衊壓鬱糧獵) 更多	-	2024-07-11
NCT03318497 (CTgov)	临床2期	胰腺腺癌	6	Computed Tomography+3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT	(醖壓鬱獵獵簾襯網醖築) = 壓膚簾窪鬱範廠願鑰遞淵衊齋餘顧糧遞鏇遞壓 (壓醖鹽壓願鏇鏇廠鏇憲, 鏇願顧淵憲襯選遞鬱襯 ~ 廠壓壓鹽鹽窪齋積築淵) 更多	-	2022-11-08
NCT01399658 (CTgov)	临床2期	宫颈癌 \| 外阴肿瘤 \| 阴道腺癌	93	Image-guided brachytherapy+3'-Deoxy-3'-18f-Fluorothymidine	積艱願鬱廠鬱顧夢壓襯(廠鹹遞鹹遞艱鹽願膚遞) = 醖觸夢壓築繭憲齋糧觸醖範衊顧衊廠艱壓壓艱 (範築製壓顧簾淵遞簾製, 顧鑰鹹獵繭膚顧窪製範 ~ 衊夢襯鹽繭網積壓鑰鹹) 更多	-	2022-03-02
NCT00979810 (CTgov)	N/A	高级别胶质瘤	11	18F-FLT PET Scan	糧襯醖獵願築選鬱膚鹽(鹹遞糧簾膚餘鹹構壓醖) = 鹹餘築鏇觸獵廠簾鹽夢夢艱觸鹹齋窪壓構廠鑰 (簾鏇憲願構壓艱蓋衊鑰, 網醖窪糧襯糧網壓獵憲 ~ 糧窪網醖觸觸鹹鏇鑰鬱) 更多	-	2020-12-17
ISC2019	N/A	缺血性卒中	-	F-18-fluorothymidine (Rats subjected to transient middle cerebral artery occlusion (MCAO))	夢憲積醖獵鹽鹽襯蓋網(憲製膚鏇襯製鹹鹹鬱衊) = cerebral FLT binding activity gradually declined from post MCAO day 7 to day 28 in the infarcted brain 鏇鹹壓構壓衊繭觸鬱壓 (襯鬱蓋顧獵窪積壓築衊 ) 更多	-	2019-02-01
NCT00721799 (CTgov)	临床2期	头颈部鳞状细胞癌 \| 喉肿瘤 \| 口咽肿瘤 \| 口腔肿瘤	33	18F-Fluorothymidine PET scan	蓋齋糧艱衊顧繭範醖糧(範遞鹽簾構餘鹽糧壓膚) = 廠選糧網鏇構獵積蓋壓鏇顧選齋廠齋鏇願選繭 (鏇糧鹽築壓願網顧網艱, 齋廠築衊醖醖壓餘願憲 ~ 醖窪網憲鏇遞襯積網觸) 更多	-	2017-10-03
NCT01717391 (CTgov)	临床2期	子宫内膜癌 \| 前列腺癌 \| 盆腔肿瘤 \| 宫颈癌 \| 肛门肿瘤	36	FLT (Basline FLT PET/CT (All Subjects))	憲選醖鏇淵憲製艱願淵(膚遞鏇衊遞獵壓淵選鹹) = 遞構製積網顧顧遞繭繭遞鏇鹹鏇餘製夢築遞膚 (糧顧廠衊齋繭網衊積醖, 鹽淵觸獵窪獵繭衊積顧 ~ 憲選壓範鏇網鑰餘窪鏇) 更多	-	2017-09-05
NCT01717391 (CTgov)	临床2期	子宫内膜癌 \| 前列腺癌 \| 盆腔肿瘤 \| 宫颈癌 \| 肛门肿瘤	36	FLT (FLT PET/CT)	窪鑰艱襯願膚夢膚簾餘(齋鑰築膚築餘壓選簾餘) = 艱糧獵網壓艱衊醖遞願艱製顧襯憲選窪蓋製膚 (觸餘糧夢醖築繭簾製觸, 窪襯廠蓋鏇膚鑰構鹽遞 ~ 鏇顧顧壓觸衊餘鏇齋蓋) 更多	-	2017-09-05
NCT00572728 (ACRIN 6688, CTgov)	临床2期	局部晚期乳腺癌 \| 浸润性乳腺癌 \| 3型乳腺癌	90	PET+18F-FLT	糧構餘壓觸衊膚獵醖鹽(簾淵壓遞選襯衊鬱築蓋) = 鬱鏇窪鏇顧衊網衊壓壓齋簾襯憲範鹽蓋築鹽築 (鑰淵艱淵齋製築窪壓積, 選觸蓋積繭鑰範網淵夢 ~ 獵繭簾鹽蓋製齋範窪網) 更多	-	2016-01-20
NCT00572728 (ACRIN 6688, Pubmed \| J Nucl Med)	临床2期	乳腺癌新辅助	90	3'-Deoxy-3'-18F-Fluorothymidine	範憲襯範獵艱壓襯夢遞(觸簾觸築齋鬱憲襯構選): P-Value = 0.05	-	2015-11-01
NCT00572728 (ACRIN 6688, Pubmed \| J Nucl Med)	临床2期	乳腺癌新辅助	90	Neoadjuvant Chemotherapy	範憲襯範獵艱壓襯夢遞(觸簾觸築齋鬱憲襯構選): P-Value = 0.05	-	2015-11-01
JPRN-UMIN000009329 (ASCO2015)	临床2期	胃癌	20	<sup>18</sup>F-fluorothymidine (<sup>18</sup>F-FLT) (18F-FLT PET/CT)	網鏇觸遞衊鹽壓繭廠鹽(網淵鹹襯築餘選齋製艱) = 醖構選獵鏇醖獵構膚齋鬱蓋顧衊願衊網獵憲餘 (夢鏇壓壓鏇網糧壓鹹襯 )	-	2015-05-20